System review on comparison of rivaroxaban and dabigatran in patients undergoing radiofrequency catheter ablation for atrial fibrillation
10.13699/j.cnki.1001-6821.2017.11.022
- VernacularTitle:利伐沙班与达比加群对心房颤动患者导管消融围术期抗凝治疗的系统评价
- Author:
Fu-Ying LIU
1
;
Rong WANG
;
Ying CHEN
;
Si-Yi LIU
;
Guo-Hua CHENG
Author Information
1. 暨南大学药学院
- Keywords:
rivaroxaban;
dabigatran;
radiofrequency catheter ablation;
Meta-analysis;
pharmacoeconomy
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(11):1032-1035
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficiency and safety of rivaroxaban and dabigatran for anticoagulant therapy which is a treatment for atrial fibrillation patients undergoing catheter ablation.Methods CNKI,VIP Database,Wangfang Database,PubMed,Web of science,EmBase and Cochrane library were searched until 2016-12-15.All clinical trials about anticoagulant therapy of rivaroxaban and dabigatran in patients undergoing catheter ablation for atrial fibrillation were selected.And research quality evaluation was done using RevMan5.3 software for Meta analysis.Minimum cost analysis method was used for economic evaluation.Results A total of 6 observational study and 1 randomized controlled trials met the inclusion criteria.Compared with dabigatran,rivaroxaban has no statistically significant differences in thromboembolism (RR =1.03,95％ CI =0.27-4.00,P ＞0.05),major bleeding (RR =1.02,95％CI =0.42-2.48,P ＞0.05),strokes (RR =0.87,95％CI =0.17-4.60,P ＞0.05),but there was statistical significance in costs between two groups(P ＜ 0.05).Conclusion Rivaroxaban and dabigatran have similar effectiveness and safety in anticoagulant therapy for patients undergoing catheter ablation for atrial fibrillation,but dabigatran has economic advantage.
